The underwriters have a 30-day option to purchase up to an additional 825,000 shares of common stock. Sequenom expects the net proceeds from the offering to be used for the development of diagnostic tests for use on its MassARRAY system and other platforms, and for general corporate purposes.
Lehman Brothers and UBS Investment Bank are acting as joint book-running managers in this offering. The co-managers for the offering are Leerink Swann & Co., Lazard Capital Markets, Oppenheimer & Co., and Rodman & Renshaw, a wholly-owned subsidiary of Rodman & Renshaw Capital Group.